Mumbai, Jan 14 :Pharmaceuticals company Aurobindo Pharma Today  said it has received a ‘warning letter’ from the USFDA for one of its API (active pharmaceutical ingredient) manufacturing facility in Hyderabad.

This action follows the recent inspection of the unit by the USFDA in August 2021, the company said in a regulatory filing.

“… with regards to the OAI classification of our unit I, an API manufacturing facility of the company in Hyderabad, we inform that the company has received a warning letter from the USFDA for the said unit,” the company said.

The company believes that this will not impact the existing business from this facility.

“The company will be engaging with the regulator and is fully committed in resolving this issue at the earliest.

The company is also committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe,” the Hyderabad-based firm added.(UNI)